Sep 22, 2016
The UK is moving closer to aligning its two approaches to regulating drug pricing — the voluntary PPRS and statutory price cuts — but the headaches are likely to continue, writes Leela Barham.
Sep 07, 2016
Pharmaceutical Executive
Big pharma has become increasingly vulnerable to larger geopolitical and macroeconomic risks—a realization that has slowly creeped into their business planning, writes William Looney.
Sep 01, 2016
It’s safe to say content marketing is here to stay, writes Peter Houston. So what is pharma doing with it?
Aug 30, 2016
The outrage over Mylan’s price hikes for its EpiPen auto-injector illustrates the many factors that keep drug pricing immune from normal economic pressures, writes Jill Wechsler.
Aug 29, 2016
Pharmaceutical Executive
William Looney compares 2002 approaches in boosting shareholder value to those of today. The fall in one particular performance metric is telling.
Aug 15, 2016
Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.
Aug 10, 2016
Pharmaceutical Executive
In the spirit of the Olympics, Casey McDonald cites some of the feel-good and not-so-good stories making waves in the competitive world of pharma.
Aug 05, 2016
Having lobbied hard to have Inter Partes Review proceedings (IPRs) enacted, the tech industry may now be regretting what it wished for, write Traci Medford-Rosow and Peter C. Richardson.
Jul 20, 2016
Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach.
Jul 13, 2016
Pharmaceutical Executive
Amid today's growing constituency of cancer survivors, oncology is testing the historic divide in medicine between what’s science and what’s social, writes William Looney.
lorem ipsum